List of Opsona Therapeutics patents | 8 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8734788 Composition and method for treatment of reperfusion injury and tissue damage	Patent 8734788 was granted and assigned to Opsona Therapeutics on May, 2014 by the United States Patent and Trademark Office.		Opsona Therapeutics	United States Patent and Trademark Office	8734788	May 27, 2014
‌ US Patent 9234046 Treatment of renal disease	Patent 9234046 was granted and assigned to Opsona Therapeutics on January, 2016 by the United States Patent and Trademark Office.		Opsona Therapeutics	United States Patent and Trademark Office	9234046	January 12, 2016
‌ US Patent 8734794 Humanised antibodies to toll-like receptor 2 and uses thereof	Patent 8734794 was granted and assigned to Opsona Therapeutics on May, 2014 by the United States Patent and Trademark Office.		Opsona Therapeutics	United States Patent and Trademark Office	8734794	May 27, 2014
‌ US Patent 9896497 Toll-like receptor 2 binding epitope and binding member thereto	Patent 9896497 was granted and assigned to Opsona Therapeutics on February, 2018 by the United States Patent and Trademark Office.	Opsona Therapeutics	Opsona Therapeutics	United States Patent and Trademark Office	9896497	February 20, 2018
‌ US Patent 10047164 Methods and compositions for the treatment of pancreatic cancer	Patent 10047164 was granted and assigned to Opsona Therapeutics on August, 2018 by the United States Patent and Trademark Office.	Opsona Therapeutics	Opsona Therapeutics	United States Patent and Trademark Office	10047164	August 14, 2018
‌ US Patent 8414887 Methods for suppressing Toll-like Receptor 4 (TLR4) function using TLR14 antagonists	Patent 8414887 was granted and assigned to Opsona Therapeutics on April, 2013 by the United States Patent and Trademark Office.		Opsona Therapeutics	United States Patent and Trademark Office	8414887	April 9, 2013
‌ US Patent 8221992 Assays for determining compounds which modulate TRAM phosphorylation	Patent 8221992 was granted and assigned to Opsona Therapeutics on July, 2012 by the United States Patent and Trademark Office.		Opsona Therapeutics	United States Patent and Trademark Office	8221992	July 17, 2012
‌ US Patent 8580255 Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody			Opsona Therapeutics	United States Patent and Trademark Office	8580255	November 12, 2013